Innovent's CLDN18.2 ADC arcotatug tavatecan hits Phase 3 primary endpoint in gastric cancer, boosting Takeda's $11.4B bet on the drug.
Innovent Biologics’ ADC candidate has passed a Phase 3 trial in advanced stomach cancer and is under priority review in China, but details of the …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
World's First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer and NDA Accepted by China NMPA
2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
A Spanish biotech banks $87M to make differentiated ADCs
ADC Therapeutics' shares plummet after patient deaths in trial of Zynlonta
ASCO: Sac-TMT’s massive phase 3 program has a jarring gap. Does Merck plan to close it?
2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Stud
Innovent, Pfizer sign oncology deal
ASCO: Roche, head held high, details oral SERD's first-line flop in breast cancer
ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma - Pharmaceutical Technology
World's First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint…
An experimental antibody-drug conjugate from Merck and Kelun-Biotech succeeded in a global Phase 3 study for the first time,…
/C O R R E C T I O N -- Innovent Biologics/
The TROP2 battle in first-line triple-negative breast cancer has officially kicked off. | A three-way battle among TROP2 ADCs in…
2026 ASCO Abstract Highlights | Innovent Announces Preliminary PoC data of IBI363 (PD-1/IL-2α-bias bispecific fusion protein) in…
The FDA has approved the TROP2-directed ADC Datroway as a first-line option for triple-negative breast cancer, giving Daiichi…
